by dyadic | May 21, 2026 | Press Releases
JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology...
by dyadic | May 19, 2026 | Press Releases
JUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology...
by dyadic | May 13, 2026 | Press Releases
Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industryCommercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with...
by dyadic | Apr 29, 2026 | Press Releases
JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology...
by dyadic | Mar 25, 2026 | Press Releases
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio,...
by dyadic | Mar 16, 2026 | Press Releases
JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) — Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing...
